Ceres Inc (CERE) News

Ceres Inc (CERE): $26.42

-0.02 (-0.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CERE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter CERE News Items

CERE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CERE News Highlights

  • For CERE, its 30 day story count is now at 4.
  • Over the past 1 day, the trend for CERE's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
  • MG, CORT and MITO are the most mentioned tickers in articles about CERE.

Latest CERE News From Around the Web

Below are the latest news stories about Cerevel Therapeutics Holdings Inc that investors may wish to consider to help them evaluate CERE as an investment opportunity.

Analysts’ Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks.

Brian Anderson on TipRanks | February 16, 2022

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter 2021 financial results and recent business updates on Tuesday, March 1, 2022 at 8:00 a.m. ET. To access the call, ple

Yahoo | February 16, 2022

Cerevel's Acute Anxiety Candidate Shows Encouraging Action In Healthy Volunteers

Cerevel Therapeutics Holdings Inc's (NASDAQ: CERE) 7.5 mg twice daily and the 25 mg twice-daily doses of darigabat demonstrated clinically meaningful and statistically significant anxiolytic activity in healthy volunteers compared with placebo. After eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses demonstrated a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the primary endpoint of the Panic Symptoms List (PSL-IV) total score. The positive contro

Yahoo | February 15, 2022

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated; resulted in no serious adverse events and no treatment-related discontinuations in the trialCerevel intends to advance development of darigabat in anxiety-related disordersConference call and webcast scheduled for today

Yahoo | February 15, 2022

Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the first half of 2024 Phase 1 trial for darigabat in acute anxiety completed; data is expected in the next several weeks Phase 2a data for CVL-871 in dementia-related apathy now expected 1H 2023; delayed from 2H 2022, due in

Yahoo | January 10, 2022

Tarbox Family Office, Inc. Buys iShares Core Total USD Bond Market ETF, iShares Core MSCI Total ...

Investment company Tarbox Family Office, Inc. (Current Portfolio) buys iShares Core Total USD Bond Market ETF, iShares Core MSCI Total International Stock ETF, BTC iShares International Aggregate Bond Fund, IGM Biosciences Inc, Fisker Inc, sells Alphabet Inc, AT&T Inc, Meta Platforms Inc, Trex Co Inc, JPMorgan Chase during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tarbox Family Office, Inc..

Yahoo | January 6, 2022

Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by Chief Medical Officer Raymond Sanchez, M.D., and Chief Scientific Officer John Renger, Ph.D., for the question-and-answe

Yahoo | January 3, 2022

One Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) insider upped their stake by 148% in the previous year

Viewing insider transactions for Cerevel Therapeutics Holdings, Inc.'s ( NASDAQ:CERE ) over the last year, we see that...

Yahoo | December 21, 2021

7 Hidden Gem Cryptos to Buy Before They Break Out

These cryptos to buy for multi-fold returns in the next few quarters are flying under the radar but have a strong utility.

Faisal Humayun on InvestorPlace | December 16, 2021

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia

Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with the potential to improve and reverse symptoms of schizophreniaCAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Herophilus, a leading biotechnology company developing neurotherapeutics to

Yahoo | December 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4743 seconds.